Finally, this study also potentially concerns other pathologies, such as other dilated cardiomyopathies and heart failure, which combine Ca2+ dysregulation and NAD+ deficit, for which an anti‐CD38 therapy could be highly relevant. This evidence concerns the gene CD38 and dilated cardiomyopathy.